Thank you for joining the weekly webinar! We are admitting audience members from the waiting room. Please allow a few moments for the webinar to begin.
HEALEY ALS Platform Trial:

- Regimen A
- Regimen B
- Regimen C
- Regimen D
- Regimen E
- Regimen F
- Regimen G

Common Protocol and Shared Infrastructure:

- Screen for eligibility
- Randomization 3:1
- Active
- Placebo

ENROLLMENT COMPLETE

ENROLLING
Enrollment Update: Regimen F and Regimen G

Participants consented to Master Protocol since RGF and RGG initiated

Participants assigned to RGF or RGG

Participants randomized within RGF or RGG
(enrollment goal ≈240 per regimen, ≈480 total)

Thank You for your partnership in ALS research

(as of 8/3/23)
59 Sites Currently Active

(as of 8/3/23)

Nova Southeastern University
Essentia Health
Texas Neurology
Mass General Hospital
University of Nebraska
Hospital for Special Care
Henry Ford Hospital
Augusta University
Beth Israel Deaconess
University of Texas HSC
University of Colorado
Ohio State University
Cedars Sinai Medical Center
Duke University
Wake Forest University
Saint Alphonsus
UMass Worcester
Lehigh Valley
Thomas Jefferson
University of South Florida
University of Pennsylvania
SUNY Upstate
University of Iowa
California Pacific Med Center
Houston Methodist
Vanderbilt University
University of Minnesota
Washington University
Barrow Neurological Institute
University of Miami
Temple University
University of Virginia
Johns Hopkins University
University of Southern CA
Holy Cross Hospital
University of Washington

University of Utah
Penn State Hershey
University of Michigan
University of Kansas
Stony Brook University
University of Cincinnati
Mayo Clinic Rochester
Northwestern University
Georgetown University
Kaiser, Los Angeles
University of Pittsburgh
Virginia Commonwealth
Med College Wisconsin
University of CA, San Fran
University of Florida, Gainesville
Providence Brain and Spine
Cleveland Clinic
George Washington University
Hackensack University
Swedish Medical Center
University of Kentucky
Dartmouth Hitchcock

Site Map & Contacts:

https://bit.ly/3g2NZr5
**Checking Site Status Online**

List of Participating Sites

Sites marked "Recruiting" are currently enrolling participants. Sites marked "Active, Not recruiting" are active in the Platform Trial (for example, they are following participants in ongoing regimens that have already completed enrollment) but are not enrolling new participants at this time.

<table>
<thead>
<tr>
<th>Site</th>
<th>State</th>
<th>Enrollment Status</th>
<th>Trial Contact Information</th>
</tr>
</thead>
<tbody>
<tr>
<td>Barrow Neurological Institute</td>
<td>AZ</td>
<td>Recruiting</td>
<td>Whitney Dailey</td>
</tr>
<tr>
<td>Cedars-Sinai Medical Center</td>
<td>CA</td>
<td>Recruiting</td>
<td>Sophia Mostowy</td>
</tr>
<tr>
<td>Forbes Norris MDA/ALS Research Center,</td>
<td>CA</td>
<td>Recruiting</td>
<td>Teji Dulai</td>
</tr>
<tr>
<td>California Pacific Medical Center</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kaiser Permanente, Los Angeles Medical Center</td>
<td>CA</td>
<td>Recruiting</td>
<td>Mary H. Berganza</td>
</tr>
</tbody>
</table>

Contact a study team near you to discuss enrollment opportunities.
Regimen G Drug Science Q&A Webinar

Recording Now Available

https://www.youtube.com/watch?v=Ij9s_KoYgBw
Patient Navigation
Central resource for people living with ALS

Phone: 833-425-8257 (HALT ALS)
E-mail: healeyalsplatform@mgh.harvard.edu

Weekly webinar registration:  
https://bit.ly/3r6Nd2L

ALS Link sign-up:  
https://bit.ly/3o2Ds3m

Upcoming Webinars:
August 10th- featuring participant perspective on lumbar puncture
August 17th- with guest speaker Gwen Petersen
August 24th- weekly Q&A webinar

*August 31st webinar canceled